Biotechnology

Cyclacel Pharma

Cyclacel Pharma released FY2025 Semi-Annual Earnings on August 14 (EST), with actual revenue of USD 0 and EPS of USD -1.62

Cyclacel Pharma released FY2025 Q2 earnings on August 13 (EST), actual revenue USD 0 (forecast USD 25K), actual EPS USD -1.5275 (forecast USD -71.9999)

Cyclacel Pharmaceuticals reports preclinical data on plogosertib for bile duct cancer

Cyclacel Pharmaceuticals Completes Series F Preferred Stock Sale

Cyclacel Pharmaceuticals Amends Swap Agreement

Cyclacel Pharmaceuticals Secures $3 Million Preferred Stock Financing

Cyclacel Pharmaceuticals Reports Q1 Earnings and Considers Merger

Cyclacel Pharma released FY2025 Q1 earnings on May 14 (EST), actual revenue USD 0 (forecast USD 25K), actual EPS USD -0.0937 (forecast USD -69.5999)

Cyclacel Pharmaceuticals Inc. Submits Beneficial Ownership Statement

Cyclacel Pharma released FY2024 Q4 earnings on April 2, 2025 (EST), actual revenue USD 0 (forecast USD 10K), actual EPS USD -79.2521 (forecast USD -69.5999)

Cyclacel Pharma released FY2024 earnings on April 2 (EST), actual revenue USD 43K (forecast USD 53K), actual EPS USD -502.4648 (forecast USD -467.9997)

Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Performance and Plans to Increase Shareholder Equity

Cyclacel Pharmaceuticals Announces $1 Million Private Placement of Convertible Preferred Stock

Cyclacel Pharmaceuticals Announces Exploration and Review of New Drugs

Cyclacel Pharma released FY2024 9 Months Earnings on November 12, 2024 (EST), with actual revenue of USD 43K and EPS of USD 0

Cyclacel Pharma released FY2024 Q3 earnings on November 12 (EST), actual revenue USD 10K (forecast USD 10K), actual EPS USD 0 (forecast USD -129.60)

Cyclacel Pharma released FY2024 Q2 earnings on August 14 After-Market EST, actual revenue USD 4 K (forecast USD 15 K), actual EPS USD 0 (forecast USD -344.3998)

Cyclacel Pharma released FY2024 Semi-Annual Earnings on August 14 After-Market EST, actual revenue USD 33K, actual EPS USD 0

Cyclacel Pharma released FY2024 Q1 earnings on May 14 After-Market EST, actual revenue USD 29K (forecast USD 0), actual EPS USD 0 (forecast USD -1.139K)

Cyclacel Pharma released FY2023 earnings on March 19 After-Market EST, actual revenue USD 420 K (forecast USD 389 K), actual EPS USD 0 (forecast USD -4.854 K)

Republic Power

Brand Engagement Network

Society Pass

Intelligent Living Application

3 E Network Tech

Globavend

CCSC Tech

Sidus Space

Tryhard

Dreamland

Adma Biologics

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel Pharma

OpGen

Vertex Pharma

Regeneron Pharma

Alnylam Pharma

Argenx

Beigene

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap